Selective Serotonine Reuptake Inhibitors (SSRI) Usage during Pregnancy

Psychiatr Danub. 2021 Spring-Summer;33(Suppl 4):1171-1176.

Abstract

Depressive disorders in pregnancy are common and generate concerns regarding their treatment. The effects of untreated maternal depressive symptoms on preterm birth, low birthweight, fetal growth restriction and postnatal complications are well known. When left untreated, depressive disorders continue postpartum and have a big impact on the patients' functioning. Selective serotonine reuptake inhibitors (SSRIs) are the first choice of treatment of depressive disorders. However, there are some concerns which should be adressed. The aim of this systematic review is to explore the SSRI usage in pregnancy. We studied the latest literature in the PubMed databases and recommendations from the guidelines. Decision to treat depression in pregnancy should be taken with careful consideration of many factors. Clinicians should weigh the use of SSRIs during pregnancy against the risk of untreated depressive disorder.

Publication types

  • Systematic Review

MeSH terms

  • Female
  • Humans
  • Infant, Newborn
  • Postpartum Period
  • Pregnancy
  • Premature Birth*
  • Selective Serotonin Reuptake Inhibitors / adverse effects

Substances

  • Serotonin Uptake Inhibitors